Journal of Intensive Care

Table 3 Average daily PTAs over 72 h in each 10,000 virtual patients receiving 20, 25 and 35 mL/kg/h continuous renal replacement therapy with selected lacosamide regimens using high target AUCs of 143–231 mg*h/L

From: Lacosamide dosing in patients receiving continuous renal replacement therapy

Selected dosing regimens		Average PTA (%) (AUC of 143–231 mg*h/L)
		CVVHD			CVVH
		Effluent rates (mL/kg/h)
		20	25	35	20	25	35
250 mg q 12 h	In TR	71.90	71.93	52.32	70.14	75.49	74.00
	Above TR	18.06	9.37	1.60	24.64	15.31	5.13
	Below TR	10.04	18.70	46.08	5.22	9.20	20.87
300 mg LD, followed by 250 mg q 12 h	In TR	70.53	73.44	57.14	64.84	72.94	77.09
	Above TR	22.65	11.72	3.00	31.80	20.58	7.39
	Below TR	6.82	14.84	39.86	3.36	6.48	15.52
350 mg LD, followed by 250 mg q 12 h	In TR	67.16	72.61	63.33	60.99	69.98	78.93
	Above TR	28.17	16.44	3.88	37.04	25.78	10.80
	Below TR	4.67	10.95	32.79	1.97	4.24	10.81
300 mg q 12 h	In TR	52.28	65.50	72.54	42.57	53.62	72.61
	Above TR	46.09	29.94	10.80	56.88	45.12	23.68
	Below TR	1.63	4.56	16.66	0.55	1.26	3.71
150 mg q 8 h	In TR	67.47	56.92	31.77	73.26	70.15	53.87
	Above TR	6.24	2.64	0.22	9.81	5.11	1.08
	Below TR	26.29	40.44	68.01	16.93	24.74	45.05
200 mg LD, followed 150 mg q 8 h	In TR	70.73	62.94	38.16	74.21	73.40	61.67
	Above TR	9.24	4.11	0.54	13.63	7.17	1.74
	Below TR	20.03	32.59	61.30	12.16	19.43	36.59
250 mg LD, followed by 150 mg q 8 h	In TR	73.19	68.83	44.87	73.40	76.55	68.46
	Above TR	12.71	5.94	0.86	18.61	10.58	3.15
	Below TR	14.10	25.23	54.27	7.99	12.87	28.39
200 mg q 8 h	In TR	57.77	67.63	70.65	48.40	58.49	73.77
	Above TR	39.75	26.31	9.00	50.56	39.89	20.76
	Below TR	2.48	6.06	20.35	1.04	1.62	5.47
250 mg LD, followed by 200 mg q 8 h	In TR	51.86	64.79	72.84	42.07	53.85	70.94
	Above TR	46.73	30.92	11.03	57.35	45.03	25.26
	Below TR	1.41	4.29	16.13	0.58	1.12	3.80

PTA probability of target attainment, CVVHD continuous venovenous hemodialysis, CVVH continuous venovenous hemofiltration, LD loading dose, TR therapeutic range, In TR: AUC in the range of 143–231 mg*h/L, respectively, above TR: AUC greater than 231 mg*h/L, respectively, below TR: AUC less than 143 mg*h/L, respectively

Back to article page

ISSN: 2052-0492

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com